These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 37498296)

  • 1. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
    Dong X; Liu T; Li Z; Zhai Y
    Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Yang W; Liu Z; Liu T
    Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden.
    Li Z; Zheng Y; Wu Z; Zhuo T; Zhu Y; Dai L; Wang Y; Chen M
    Medicine (Baltimore); 2023 Jan; 102(3):e32686. PubMed ID: 36701707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
    Wang Y; Liu T; Zhang K; Huang RH; Jiang L
    Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
    Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
    BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3.
    Ling ZN; Hong LL; Wu J; Ling ZQ
    Sci Rep; 2024 Feb; 14(1):3030. PubMed ID: 38321173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A pan-cancer analysis of TTC9A expression level and its correlation with prognosis and immune microenvironment].
    Yao Y; Liu J; Zhou X; Liu Z; Qiu S; He Y; Zhou X
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jan; 44(1):70-82. PubMed ID: 38293978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 15. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
    Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
    Front Immunol; 2022; 13():903461. PubMed ID: 35663977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCPAD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer.
    Feng L; Yang Y; Lin Z; Cui M; Jin A; Cui A
    Genes Environ; 2024 Jan; 46(1):2. PubMed ID: 38172945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
    Yang Q; Zeng S; Liu W
    PeerJ; 2023; 11():e15019. PubMed ID: 36949759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pan-cancer analysis of the prognostic implication and oncogenic role of tubulin epsilon and delta complex 2 (TEDC2) in human tumors.
    Liu Y; Zhu J; Shen J; Lu Y; Pan K; Tong C; Wang Y
    Front Immunol; 2023; 14():1272108. PubMed ID: 38239349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.